Mauricio Burotto

8.5k total citations · 5 hit papers
101 papers, 3.7k citations indexed

About

Mauricio Burotto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Mauricio Burotto has authored 101 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Oncology, 56 papers in Pulmonary and Respiratory Medicine and 27 papers in Cancer Research. Recurrent topics in Mauricio Burotto's work include Cancer Immunotherapy and Biomarkers (36 papers), Renal cell carcinoma treatment (35 papers) and Cancer Genomics and Diagnostics (17 papers). Mauricio Burotto is often cited by papers focused on Cancer Immunotherapy and Biomarkers (36 papers), Renal cell carcinoma treatment (35 papers) and Cancer Genomics and Diagnostics (17 papers). Mauricio Burotto collaborates with scholars based in United States, Spain and France. Mauricio Burotto's co-authors include Victoria L. Chiou, Elise C. Kohn, Jean C. Lee, Vinay Prasad, Chul Kim, Andrae Vandross, Robert J. Motzer, Toni K. Choueiri, Julia Wilkerson and Tito Fojo and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Mauricio Burotto

94 papers receiving 3.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The MAPK pathway across different malignancies: A new perspective

2014 723 citations Mauricio Burotto et al. profile →
Pseudoprogression and Immune-Related Response in Solid Tumors

2015 648 citations Mauricio Burotto et al. Journal of Clinical Oncology profile →
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

2020 347 citations Laurence Albigès, Mauricio Burotto et al. ESMO Open profile →
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

2022 177 citations Robert J. Motzer, Mauricio Burotto et al. The Lancet Oncology profile →
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

2023 89 citations Toni K. Choueiri, Laurence Albigès et al. profile →

Peers

Countries citing papers authored by Mauricio Burotto

Since Specialization

Citations

This map shows the geographic impact of Mauricio Burotto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mauricio Burotto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mauricio Burotto more than expected).

Fields of papers citing papers by Mauricio Burotto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mauricio Burotto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mauricio Burotto. The network helps show where Mauricio Burotto may publish in the future.

Co-authorship network of co-authors of Mauricio Burotto

This figure shows the co-authorship network connecting the top 25 collaborators of Mauricio Burotto. A scholar is included among the top collaborators of Mauricio Burotto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mauricio Burotto. Mauricio Burotto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma 2025 ·Annals of Oncology ·Ana Arance, Miguel‐Ángel Berciano‐Guerrero, Jun Guo, (unknown), Paolo A. Ascierto, Mauricio Burotto, Laurent Mortier, (unknown), Vanna Chiarion‐Sileni, Jacob Schachter, Xiang Zhang, (unknown), M. Del Vecchio, Chinyere E. Okpara, Corina E. Dutcus, Jie Zhang, Scott J. Diede, Tobias Neff, Georgina V. Long	0
2	Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial 2025 ·European Urology ·Matthew D. Galsky, Michiel S. van der Heijden, Thomas Powles, Mélanie Claps, Mauricio Burotto, Michael Schenker, Juan Pablo Sade, Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, Yüksel Ürün, Dingwei Ye, Begoña P. Valderrama, Yoshihiko Tomita, Ruiyun Jiang, Jeiry Filian, Lily Wang, (unknown), Guru Sonpavde	0
3	Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study 2025 ·Clinical Breast Cancer ·Joyce O’Shaughnessy, Susana Sousa, Josefina Cruz Jurado, Lesley Fallowfield, Päivi Auvinen, (unknown), Ana Cvetanović, Sharon Wilks, (unknown), Mauricio Burotto, Thomas Boulet, (unknown), (unknown), Peter C. Trask, (unknown), (unknown), Ljiljana Stamatović	0
4	Understanding microRNA-Mediated Chemoresistance in Colorectal Cancer Treatment 2025 ·International Journal of Molecular Sciences ·Guillermo J. Valenzuela, Héctor R. Contreras, Katherine Marcelain, Mauricio Burotto, (unknown)	3
5	LBA53 Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study 2024 ·Annals of Oncology ·(unknown), Mauricio Burotto, (unknown), Martin Reck, (unknown), (unknown), (unknown), (unknown), (unknown), Vamsidhar Velcheti, (unknown), (unknown), (unknown), (unknown), Munir Chowdhury, Thomas Spires, (unknown), Manuel Cobo	10
6	Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial. 2024 ·Journal of Clinical Oncology ·Matt D. Galsky, Guru Sonpavde, Thomas Powles, Mélanie Claps, Mauricio Burotto, Michael Schenker, Juan Pablo Sade, Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, Yüksel Ürün, Dingwei Ye, Begoña P. Valderrama, Yoshihiko Tomita, Jeiry Filian, Lily Wang, Daniela Purcea, Michiel Simon Van Der Heijden	11
7	Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial 2024 ·ESMO Open ·Thomas Powles, Mauricio Burotto, Bernard Escudier, Andrea B. Apolo, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Camillo Porta, Carlos H. Barrios, Martin Eduardo Richardet, Howard Gurney, Elizabeth R. Kessler, Yoshihiko Tomita, Jens Bedke, Saby George, Christian Scheffold, (unknown), (unknown), Robert J. Motzer, Toni K. Choueiri	31
8	Targeting HIF-2α: the role of belzutifan in clear cell renal carcinoma management 2024 ·Expert Review of Clinical Pharmacology ·(unknown), (unknown), (unknown), (unknown), Mauricio Burotto	3
9	LBA74 Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC) 2024 ·Annals of Oncology ·Brian I. Rini, (unknown), Laurence Albigès, (unknown), (unknown), Mauricio Burotto, Pooja Ghatalia, Roberto Iacovelli, Elaine T. Lam, Elena Verzoni, (unknown), Walter M. Stadler, Christian Kollmannsberger, Bohuslav Melichar, B. Venugopal, J. Lin, (unknown), Donna Vickery, Toni K. Choueiri, T.B. Powles	3
10	Subcutaneous (SC) nivolumab (NIVO) vs intravenous (IV) NIVO in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Safety and patient-reported outcomes (PROs) of the randomized phase 3 CheckMate 67T trial. 2024 ·Journal of Clinical Oncology ·María T. Bourlon, Laurence Albigès, Matías Chacón, (unknown), José Maurício Mota, (unknown), Mauricio Burotto, Murilo Luz, J. Menezes, (unknown), Marco Maruzzo, Sergio Bracarda, (unknown), Zhuoxin Yu, (unknown), Matthew Dixon, Saby George	2
11	LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial 2023 ·Annals of Oncology ·Michiel S. van der Heijden, Guru Sonpavde, Thomas Powles, Andrea Necchi, Mauricio Burotto, Michael Schenker, (unknown), Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, (unknown), (unknown), Zhisong He, Begoña P. Valderrama, (unknown), (unknown), Daniela Purcea, Federico Nasroulah, Matt D. Galsky	9
12	Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial 2023 ·Journal of Thoracic Oncology ·James Chih‐Hsin Yang, Geoffrey Liu, Shun Lü, Jianxing He, Mauricio Burotto, Myung‐Ju Ahn, Dong‐Wan Kim, Xiaoqing Liu, Yanqiu Zhao, Sylvie Vincent, Jiani C. Yin, Xin Ma, Huamao Mark Lin, Sanjay Popat	28
13	97P Efficacy and safety of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer: Long-term data from the PHranceSCa study 2023 ·ESMO Open ·Joyce O’Shaughnessy, (unknown), Josefina Cruz Jurado, Lesley Fallowfield, Päivi Auvinen, (unknown), Ana Cvetanović, Sharon Wilks, (unknown), Mauricio Burotto, Thomas Boulet, (unknown), (unknown), Peter C. Trask, (unknown), (unknown), (unknown)	1
14	64O Lenvatinib plus pembrolizumab, pemetrexed, and a platinum (len + pembro + chemo) as first-line therapy for metastatic non squamous non-small cell lung cancer (NSCLC): Phase III LEAP-006 study 2023 ·Immuno-Oncology Technology ·Roy S. Herbst, Byoung Chul Cho, Caicun Zhou, Mauricio Burotto, Manuel Cobo, Mehmet Alı Nahıt Şendur, Vladimir Moiseyenko, Bogdan Żurawski, Ignacio Casarini, Makoto Nishio, Rina Hui, Elvire Pons‐Tostivint, Julia Dudnik, (unknown), Chinyere E. Okpara, Lei Yin, Yun Luo, Niyati Bhagwati, Delvys Rodríguez‐Abreu	3
15	PCN53 Grade 3/4 Adverse Event (AE) Costs of Nivolumab Plus Ipilimumab (N+I) Versus Nivolumab Plus Cabozantinib (N+C) and Pembrolizumab Plus Axitinib (P+A) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC) 2021 ·Value in Health ·Bradley A. McGregor, Daniel M. Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suárez, María T. Bourlon, (unknown), Ella X. Du, (unknown), (unknown), Keith A. Betts, (unknown), Toni K. Choueiri	2
16	PCN92 Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib (N+C) Versus Sunitinib (S) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC) 2021 ·Value in Health ·Daniel M. Geynisman, Bradley A. McGregor, Mauricio Burotto, Camillo Porta, (unknown), María T. Bourlon, (unknown), Ella X. Du, (unknown), (unknown), (unknown), (unknown), Toni K. Choueiri	1
17	Potential use of n-3 PUFAs to prevent oxidative stress-derived ototoxicity caused by platinum-based chemotherapy 2020 ·Free Radical Biology and Medicine ·(unknown), Mauricio Burotto, Mauricio A. Retamal, (unknown), Christian Caglevic, Juan G. Gormaz	4
18	Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins 2015 ·Proceedings of the National Academy of Sciences ·Marianne S. Poruchynsky, Edina Komlódi-Pásztor, Shana Y. Trostel, Julia Wilkerson, Marie Regairaz, Yves Pommier, Xu Zhang, Tapan K. Maity, Robert W. Robey, Mauricio Burotto, Dan L. Sackett, Udayan Guha, Antonio Tito Fojo	150
19	Non-inferiority trials: why oncologists must remain wary 2015 ·The Lancet Oncology ·Mauricio Burotto, Vinay Prasad, Tito Fojo	16
20	Hypoadiponectinemia and its Association with Liver Fibrosis in Morbidly Obese Patients 2010 ·Obesity Surgery ·(unknown), Arnoldo Riquelme, Nancy Solı́s, Margarita Pizarro, Alex Escalona, Mauricio Burotto, (unknown), (unknown), (unknown), (unknown), (unknown), Arturo Morales, René Baudrand, Gonzalo Carrasco-Aviño, Angélica Domínguez, Oslando Padilla, Manuel Espinoza, Juan Francisco Miquel, Flavio Nervi, Marco Arrese	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact